Financhill
Back

Regeneron Pharmaceuticals 10K Form

Buy
62

REGN
Regeneron Pharmaceuticals

Last Price:
962.38
Seasonality Move:
3.61%

7 Day Trial

ALL ACCESS PASS

$ 7

Receive REGN News And Ratings

See the #1 stock for the next 7 days that we like better than REGN

REGN Financial Statistics

Sales & Book Value

Annual Sales: $13.12B
Cash Flow: $776.2M
Price / Cash Flow: 29.84
Annual Sales: $237.37
Price / Book: 4.07

Profitability

EPS (TTM): 34.75000
Net Income (TTM): $3.95B
Gross Margin: $11.3B
Return on Equity: 16.33%
Return on Assets: 12.74%

Regeneron Pharmaceuticals Earnings Forecast

Key Regeneron Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 34 years for REGN is 86.16%.
  • The Selling, General & Administrative Expenses for REGN have been equal to 20.06% of Gross Profit Margin.
  • The Research & Development expenses have been 33.84% of Revenue.
  • The Interest Expense is 1.85% of Operating Income.
  • The Net Earning history of REGN is 30.14% of Total Revenues.
  • Per Share Earnings over the last 34 years have been positive in 18 years.

Regeneron Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: S&P500
Industry: Biotechnology
Sector: Healthcare
Current Symbol: REGN
CUSIP: 75886F
Website: regeneron.com

Debt

Debt-to-Equity Ratio: 0.08
Current Ratio: 5.69
Quick Ratio: 4.82

Price-to-Earnings

Trailing P/E Ratio: 27.67
Forward P/E Ratio: 20.35

REGN Technical Analysis vs Fundamental Analysis

Buy
62
Regeneron Pharmaceuticals (REGN) is a Buy

Is Regeneron Pharmaceuticals a Buy or a Sell?